Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep 29.
doi: 10.1038/s41590-025-02288-3. Online ahead of print.

Plasmacytoid dendritic cells are dispensable or detrimental in murine systemic or respiratory viral infections

Affiliations

Plasmacytoid dendritic cells are dispensable or detrimental in murine systemic or respiratory viral infections

Clemence Ngo et al. Nat Immunol. .

Abstract

Plasmacytoid dendritic cells (pDCs) are major producers of type I/III interferons. As interferons are crucial for antiviral defense, pDCs are assumed to play an essential role in this process; however, robust evidence supporting this dogma is scarce. Genetic or pharmacological manipulations that eliminate pDCs or disrupt their interferon production often affect other cells, confounding interpretation. Here, to overcome this issue, we engineered pDC-less mice that are specifically and constitutively devoid of pDCs by expressing diphtheria toxin under coordinated control of the Siglech and Pacsin1 genes, uniquely coexpressed in pDCs. pDC-less mice mounted protective immunity against systemic infection with mouse cytomegalovirus and showed higher survival and less lung immunopathology to intranasal infection with influenza virus and SARS-CoV-2. Thus, contrary to the prevailing dogma, we revealed that pDCs and their interferons are dispensable or deleterious during several viral infections. pDC-less mice will enable rigorously reassessing the roles of pDCs in health and disease.

PubMed Disclaimer

Conflict of interest statement

Competing interests: F.F., B.M., A.Z., M.D. and E.T. are inventors on a patent application filed on the targeting of pDCs to treat certain respiratory viral infections. The other authors declare no competing interests.

References

    1. Tomasello, E., Pollet, E., Vu Manh, T. P., Uze, G. & Dalod, M. Harnessing mechanistic knowledge on beneficial versus deleterious IFN-I effects to design innovative immunotherapies targeting cytokine activity to specific cell types. Front. Immunol. 5, 526 (2014). - PubMed - PMC
    1. Broggi, A. et al. Type III interferons disrupt the lung epithelial barrier upon viral recognition. Science 369, 706–712 (2020). - PubMed - PMC
    1. Major, J. et al. Type I and III interferons disrupt lung epithelial repair during recovery from viral infection. Science 369, 712–717 (2020). - PubMed - PMC
    1. Reizis, B. Plasmacytoid dendritic cells: development, regulation, and function. Immunity 50, 37–50 (2019). - PubMed - PMC
    1. Ngo, C., Garrec, C., Tomasello, E. & Dalod, M. The role of plasmacytoid dendritic cells (pDCs) in tissue immunity during viral infections and beyond. Cell Mol. Immunol. 21, 1008–1035 (2024). - PubMed - PMC

LinkOut - more resources